We are live on ! Find out more
BSTC

BioSpecifics Technologies Corp.
BSTC

Delisted

BSTC was delisted on the 1st of December, 2020.

116 hedge funds and large institutions have $294M invested in BioSpecifics Technologies Corp. in 2020 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 44 increasing their positions, 38 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

31% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 13

16% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 38

13% more capital invested

Capital invested by funds: $262M → $294M (+$32.8M)

3% more funds holding

Funds holding: 113116 (+3)

Holders
116
Holders Change
+3
Holders Change %
+2.65%
% of All Funds
2.38%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
17
Increased
44
Reduced
38
Closed
13
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
UBS Group
76
UBS Group
Switzerland
$230K -$112K -1,940 -34%
SG Americas Securities
77
SG Americas Securities
New York
$230K +$90.2K +1,559 +71%
SI
78
Shaker Investments
Ohio
$218K
Barclays
79
Barclays
United Kingdom
$210K +$80.2K +1,386 +68%
DA
80
Denali Advisors
California
$203K +$24.3K +420 +14%
SCP
81
Seizert Capital Partners
Michigan
$203K +$192K +3,312 New
Bank of America
82
Bank of America
North Carolina
$200K +$17.5K +302 +10%
IA
83
IndexIQ Advisors
New York
$192K +$182K +3,140 New
MIM
84
MetLife Investment Management
New Jersey
$186K
Morgan Stanley
85
Morgan Stanley
New York
$174K -$169K -2,920 -51%
GC
86
Globeflex Capital
California
$165K +$156K +2,700 New
MF
87
Manchester Financial
California
$163K +$2.89K +50 +2%
MLICM
88
Metropolitan Life Insurance Company (MetLife)
New York
$129K
Citigroup
89
Citigroup
New York
$119K +$6.07K +105 +6%
MAM
90
Meeder Asset Management
Ohio
$98K
Legal & General Group
91
Legal & General Group
United Kingdom
$78K -$1.1K -19 -1%
Nisa Investment Advisors
92
Nisa Investment Advisors
Missouri
$73K -$481K -8,320 -87%
TRCT
93
Tower Research Capital (TRC)
New York
$70K +$66.4K +1,148 New
APA
94
American Portfolios Advisors
New York
$65.9K
FANJ
95
Financial Architects (New Jersey)
New Jersey
$60K +$4.45K +77 +8%
CAPTRUST Financial Advisors
96
CAPTRUST Financial Advisors
North Carolina
$58K +$52.9K +915 New
PAG
97
Private Advisor Group
New Jersey
$54K +$51.3K +887 New
GT
98
Glenmede Trust
Pennsylvania
$43K -$27.7K -479 -40%
CAN
99
Cetera Advisor Networks
California
$41K +$38.8K +670 New
US Bancorp
100
US Bancorp
Minnesota
$37K -$2.89K -50 -8%

BSTC Hedge Fund Activity: Q2 2020 in Review

116 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in BioSpecifics Technologies Corp. (BSTC) for Q2 2020, worth a combined $294M — up 13% from $262M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new BSTC positions and 13 closed out — a net gain of 4 holders — while 44 added to existing stakes and 38 trimmed.

The largest buyer was Punch & Associates Investment Management, opening a new position worth an estimated $2.89M. The largest seller was Goldman Sachs, cutting an estimated $5.88M.

  • 116 institutional investors held BioSpecifics Technologies Corp. (BSTC) as of Q2 2020, up from 113 in Q1 2020.
  • Funds reported $294M of BioSpecifics Technologies Corp. stock for Q2 2020, up 13% quarter-over-quarter.
  • 17 funds opened new BioSpecifics Technologies Corp. positions in Q2 2020 and 13 closed out, a net change of +4 holders.
  • The largest BioSpecifics Technologies Corp. buyer in Q2 2020 was Punch & Associates Investment Management, an estimated $2.89M added.
  • The largest BioSpecifics Technologies Corp. seller in Q2 2020 was Goldman Sachs, an estimated $5.88M sold.

Based on aggregated 13F filings for Q2 2020.